Identifying sorafenib benefit among patients with hepatocellular carcinoma: A transcriptomic and genomic approach

This study identifies the KUSS50, a novel 50-gene signature, as a predictive biomarker for identifying patients with hepatocellular carcinoma (HCC) who are likely to benefit from sorafenib treatment. The findings have significant implications for the clinical management of HCC, particularly in optimizing treatment strategies and enhancing patient outcomes. The ability to predict the benefit of sorafenib treatment with high specificity allows for more personalized therapy, reducing unnecessary exposure to ineffective treatments. This approach can be directly applied by clinicians to improve treatment selection, ultimately leading to better patient outcomes. Additionally, understanding the molecular mechanisms underlying the KUSS50-defined subtypes may pave the way for new therapeutic strategies and interventions aimed at improving the efficacy of sorafenib and other treatments in patients with HCC.